Organon Patent-Cliff Exposure & CMS Drug Spending Portfolio
Organon (Jersey City, NJ): 30 reconciled FDA prescription therapies (26.8% 2025 to 2030 cliff risk), $696.7M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Jersey City, NJ |
| Reconciled FDA Portfolio Therapies | 30 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 26.8% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $696.7M |
| 2024 Medicare Part D Spend | $234.9M |
| 2024 Medicaid Spend | $461.8M |
| California HCAI SB 17 Filings | 2 WAC filings (max 67.5% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Organon across sibling Meru public-data platforms.